Compare KOSS & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOSS | GBIO |
|---|---|---|
| Founded | 1953 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6M | 35.4M |
| IPO Year | N/A | 2020 |
| Metric | KOSS | GBIO |
|---|---|---|
| Price | $4.85 | $5.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 25.6K | ★ 57.4K |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $13,493,080.00 | ★ $15,270,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.58 | N/A |
| 52 Week Low | $4.00 | $3.00 |
| 52 Week High | $8.59 | $14.20 |
| Indicator | KOSS | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 51.05 | 47.21 |
| Support Level | $4.81 | $5.14 |
| Resistance Level | $4.99 | $5.38 |
| Average True Range (ATR) | 0.19 | 0.25 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 71.43 | 49.35 |
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.